What is the bull case for STAAR Surgical Company (STAA)?

Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16) over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate. China grew sequentially in Q2 on normalized distributor operations. This is the second consecutive quarter of clean channel behaviour after the 2025 destocking that took shares to a $15.59 low. Q1 China contributed $47.4M of $93.5M total. Q1 2026 (2026-05-13) was a genuine beat: net sales $93.52M…

What is the bear case for STAAR Surgical Company (STAA)?

An in-line pre-announcement drew an 8.8% selloff. Companies pre-announce to control a narrative; the market's response to a headline that met consensus indicates positioning was leaning on a sequential acceleration that did not arrive. Q1 $93.5M into Q2 ">$90M" is a sequential step down. The easy comparisons expire now. Q2 2025's $44.3M was the destocking trough. From Q3 2026 the base normalizes, and triple-digit YoY growth headlines stop doing the narrative work. Price…

Dossier · STAA · Dormant

STAA · STAAR Surgical Company · Stock research

Q: Is STAA a buy?

orbyd does not issue buy or sell ratings — it publishes a dated, falsifiable thesis and the exact trigger that would prove it wrong. China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the June 18 standstill expiry, and leadership is still interim. Aug 12 print is the next binary.

LOW Earnings inflection Catalyst · 2026-08-12 medtech-diagnostics m-and-a-special-situations semi-foundry-equipment

Last analysed · 2026-07-19T11:44:04+00:00

Current thesis

China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the June 18 standstill expiry, and leadership is still interim. Aug 12 print is the next binary.

Invalidation trigger

A weekly close below $23.50 loses the rising 200-day and confirms the July 17 gap as a trend break rather than a flush; secondary break is the 2026-08-12 Q2 report showing China net sales flat-to-down sequentially or EMEA weakness spreading beyond the Middle East.

Thesis status

Open commitment catalyst in 24dscored if the trigger above fires How this is scored →

Latest analysis and events for STAA — 2026-07-19

As of 2026-07-19, orbyd's latest analysis for STAAR Surgical Company (STAA): China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the June 18 standstill expiry, and leadership is still interim. Aug 12 print is the next binary.

Invalidation trigger: A weekly close below $23.50 loses the rising 200-day and confirms the July 17 gap as a trend break rather than a flush; secondary break is the 2026-08-12 Q2 report showing China net sales flat-to-down sequentially or EMEA weakness spreading beyond the Middle East.

Next dated event on file: 2026-08-12 — catalyst in 24d.

Current Thesis

STAAR Surgical sells the EVO/EVO+ ICL, an implantable collamer lens marketed as a permanent alternative to LASIK, with revenue concentrated in China. The frame has now rotated twice: first out of a merger-arbitrage special situation, and as of this week out of the clean China-recovery momentum leg that replaced it. On July 16 (after the close) the company pre-announced Q2 net sales "in excess of $90 million" against $44.3M in Q2 2025 a +103% YoY figure that landed roughly on the $90.2M consensus and above Canaccord's $88.4M model. The market sold it: shares gapped from a $28.98 close to a $26.75 open on July 17 and finished $26.44, down 8.76%, cutting through the $29.43 50-day. The reason the tape disagreed with the headline is sequential. Q1 2026 printed $93.52M; Q2 came in below that, with EMEA down a low-single-digit percentage on Middle East conflict disruption offsetting sequential China growth, double-digit Americas gains, and double-digit EMEA growth excluding the Middle East. The comp math also turns here Q2 2025's $44.3M was the destocking trough, so the triple-digit YoY headlines end with this quarter. What remains is a mid-cap ophthalmic device business at roughly $1.3B market cap, $290M TTM revenue, still loss-making on a TTM basis (-$21.03M, EPS -$0.42), trading at a 34x forward multiple with a broken 50-day and a consensus target ($27.81 from the eleven-analyst Hold-skewed panel; $29.67 on the broader Buy tally) sitting at or under spot. That combination does not support a fresh momentum entry.

Bullish and bearish views on STAAR Surgical Company

The model's bull view on STAAR Surgical Company (STAA), in brief: Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16) over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate. The bear view: An in-line pre-announcement drew an 8.8% selloff. Both cases follow in full.

Bull Case

Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16) over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate.
China grew sequentially in Q2 on normalized distributor operations. This is the second consecutive quarter of clean channel behaviour after the 2025 destocking that took shares to a $15.59 low. Q1 China contributed $47.4M of $93.5M total.
Q1 2026 (2026-05-13) was a genuine beat: net sales $93.52M (+119.6% YoY), non-GAAP EPS $0.29 against $0.08 consensus, GAAP $0.10 against roughly $0.05, with net income swinging to +$5.2M from -$54.2M.
The weakness is geographic and identifiable, not demand-side. EMEA excluding the Middle East grew double digits; the Americas grew double digits. The drag is one region under active conflict disruption.
Wedbush reiterated Outperform with a $40 target on 2026-07-16, holding the thesis it upgraded to on 2026-05-29 (from Neutral, PT lifted from $26) that STAAR is at or near a full China rebound inflection.
Balance sheet gives the recovery runway: quick ratio 4.31, current ratio 5.12, debt-to-equity 0.09.
A ~31% holder with three board seats. Broadwood Partners killed Alcon's $30.75/share ($1.6B) bid at the January 6 2026 special meeting arguing a standalone path worth materially more, then took board representation via the January 15 cooperation agreement alongside Yunqi Capital (6.5%). That block is not a seller here.

Bear Case

An in-line pre-announcement drew an 8.8% selloff. Companies pre-announce to control a narrative; the market's response to a headline that met consensus indicates positioning was leaning on a sequential acceleration that did not arrive. Q1 $93.5M into Q2 ">$90M" is a sequential step down.
The easy comparisons expire now. Q2 2025's $44.3M was the destocking trough. From Q3 2026 the base normalizes, and triple-digit YoY growth headlines stop doing the narrative work.
Price structure has broken. The 50-day at $29.43 is now overhead resistance rather than support; the 200-day sits at $23.80. The stock is 26% off its $35.87 52-week high with no reclaim attempt yet.
The M&A binary is spent. The June 18 2026 annual meeting the same date Broadwood's standstill on demanding a special meeting expired produced director re-elections, a 3.9M-share equity plan increase, auditor ratification and a passing say-on-pay vote, with no sale process, strategic review, or special-meeting demand on the record. A month later there is still nothing.
Leadership has been interim for six months. Warren Foust (President/COO) and Deborah Andrews (CFO) have run the company as co-CEOs since February 1 2026, each on a $375,000 RSU grant, while a permanent-CEO search stays open. Chair Yeu and ex-CEO Farrell left the board in January.
Analyst dispersion is a warning, not an opportunity. The panel splits 3 Buy / 6 Hold / 2 Sell, with Wells Fargo at $25, Canaccord at $32 and Wedbush at $40. Consensus $27.81 is a few percent above spot; the $40 case requires the China ramp to re-accelerate, and the $25 case is already nearly satisfied.
China remains over half the revenue base with Q1 trade receivables running a higher share (57%) than sales (51%). Collectability and sell-in timing stay live risks that a single soft quarter would expose.
Still unprofitable on a trailing basis -$21.03M net income, -$0.42 EPS against a 34x forward multiple.

Setup & Price Structure

Shares closed $26.44 on 2026-07-17 after a gap-down from $28.98, breaking the $28–32 post-Q1 consolidation and losing the $29.43 50-day in a single session. The 200-day at $23.80 is the next structural reference, roughly 10% lower, and it is still rising the range between here and there is where the tape decides whether this is a shakeout inside an uptrend or the start of a rollover. Beta is 1.23; institutional ownership is 96.7%, so float mechanics amplify repositioning around news like this. A momentum framework has nothing to buy in a name that just lost its 50-day on a fundamental release; the constructive version requires a higher low above the 200-day and a reclaim of $29.43 on volume. Averaging into the gap because Wedbush carries a $40 target is exactly the wrong instinct here the target predates the sequential deceleration.

Catalyst Calendar (next 30 days)

2026-08-12 Q2 2026 full results and conference call (company-stated date; note some data vendors carry 2026-08-05, treat the company release as authoritative). The revenue line is already known; the variables are gross margin against the ~75% framing, the 2026 spend plan near $225M, China trade receivables versus sell-in, and any full-year commentary.
2026-08-14 Q2 2026 13F deadline. Broadwood's and Yunqi's June-quarter positioning becomes visible; continued accumulation versus a pause is the cleanest read on whether the standalone case still has its anchor holder behind it.
Undated, live permanent CEO announcement. The search has been open since February 2026; a credible external hire is the single event most likely to re-rate the standalone narrative.
Undated, ongoing Middle East conflict headlines. Management explicitly warned that intensifying geopolitical and macroeconomic pressure could weigh on future revenue growth, making EMEA a recurring quarterly swing factor.

What Would Change Our Mind

The constructive case turns back on if the August 12 print shows China accelerating sequentially with gross margin at or above 75% and trade receivables falling back toward the sales share, and price reclaims the $29.43 50-day on expanding volume that would reframe the July 17 gap as a liquidation flush rather than a trend break. A permanent CEO with refractive-surgery commercial credentials, or a fresh Broadwood open-market tranche disclosed via Form 4 into this weakness, would each add weight. Conversely, a Q2 report showing China net sales flat-to-down sequentially, or EMEA weakness spreading beyond the Middle East, confirms that the recovery leg has already been priced and paid out.

Correlation Notes

STAA trades as a China-elective-procedure proxy wearing a medtech label. Its correlation is less with the US medtech complex than with Chinese discretionary consumption and premium elective-surgery volumes the same demand pool that drove the 2025 destocking collapse. Peer read-throughs come from Alcon (the failed acquirer and the dominant refractive/cataract franchise), Bausch + Lomb and Glaukos on ophthalmic device demand, and RxSight on premium-lens elective spending. Because more than half of revenue clears through Chinese distributors, the name also carries a channel-inventory factor absent from most US-domiciled device peers: reported sales can lead or lag true implant volume by a quarter, which is what made both the 2025 crash and the 2026 recovery larger than end-demand justified. Ownership concentration Broadwood at ~31%, Yunqi at 6.5%, institutions at 96.7% means the effective float is small and moves are exaggerated in both directions on position changes.

Notes

THEME CORRECTION: prior dossier mis-tagged as biotech-precision-therapeutics / rare-disease-approvals. STAA is ophthalmic medtech (EVO/EVO+ ICL myopia implants), heavily China-levered. Not a therapeutics name.
Deal history: Alcon $28 (Aug 2025) -> $30.75 amended -> REJECTED at Jan 6 2026 special meeting -> terminated. Don't anchor entries to the dead takeout price.
Activist: Broadwood Partners owns ~31%, holds board seats, repeatedly buying in 2026 (Q1 ~$21M + $41M/$8.8M/$606k tranches). Standstill (no special-meeting demand) EXPIRES June 18 2026 = same day as annual meeting.
China concentration risk: Q1 China distributors = 51% of net sales but 57% of trade receivables -> watch collectability / sell-in pull-forward. 2025 China destocking took the stock to a $15.59 low.
Earnings cadence: Q1 reported 2026-05-13; Q2 ~early Aug 2026 (confirm exact date on investors.staar.com before any blackout-window sizing).
PT dispersion: consensus ~$29.67 (≈ spot) vs Wedbush $40 (May 29 2026) vs Broadwood $50 upside above ~$30 is M&A/activist-contingent, not organic.
THEME: STAA is ophthalmic medtech (EVO/EVO+ ICL myopia implants), heavily China-levered NOT a biotech/therapeutics name. Prior dossiers mis-tagged it; do not revert.
Deal history: Alcon $28 (Aug 2025) -> $30.75 amended -> REJECTED at Jan 6 2026 special meeting -> terminated. ISS called the process 'deeply flawed' (board relied on single bidder). Don't anchor entries to the dead takeout price.
Activist: Broadwood Partners ~31.1%, three board seats (Bradsher + LeBuhn; Yunqi's Wang also added). Q1 2026 buy ~1.1M sh (~$21M, flagged June 1 2026 Motley Fool 13F note). Standstill (no special-meeting demand) EXPIRES June 18 2026 = same day as annual meeting.
Leadership is INTERIM: Co-CEOs Warren Foust (Pres/COO) + Deborah Andrews (CFO) since Feb 1 2026; permanent-CEO search open. Chair Yeu and ex-CEO Farrell stepped off the board Jan 2026.
China = >50% of Q1 net sales ($47.4M of $93.5M). Watch trade-receivables share vs revenue share for collectability / sell-in pull-forward the 2025 destocking dynamic took the stock to $15.59.
Management DECLINED formal FY revenue guidance (May 13 call); framed 2026 spend ~$225M, gross margin ~75%; all China EVO/EVO+ supply moving to Switzerland by end-2026 to dodge US tariffs.
PT dispersion (2026): consensus ~$27.81 (BELOW spot) vs Wedbush $40 (May 29) / Canaccord $32 / Stifel $31 / Wells Fargo $25 / Broadwood $50. Upside above ~$30 is M&A/activist-contingent, not organic.
June 18 is a binary event, not a momentum leg outside the core narrative-velocity edge; treat as event/special-situation, low conviction.
THEME: STAAR is ophthalmic medtech (EVO/EVO+ ICL myopia implants), heavily China-levered NOT a biotech/therapeutics name. Prior dossiers mis-tagged it as rare-disease/precision-therapeutics; do not revert.
ELAPSED CATALYST: June 18 2026 annual meeting + Broadwood standstill expiry passed quietly 7 directors elected (~40.5–41.2M votes each), equity plan +3.9M shares approved, BDO ratified, say-on-pay passed. NO sale process, strategic review, or special-meeting demand announced. The near-term M&A binary deflated; activist lever is now un-gated but unexercised.
Deal history: Alcon $28 (Aug 2025) -> $30.75 amended -> REJECTED at Jan 6 2026 special meeting -> terminated. ISS called the process 'deeply flawed' (board relied on a single bidder). Don't anchor entries to the dead takeout price.
Activist: Broadwood Partners ~31.1%, three board seats (Bradsher + LeBuhn + Yunqi's Wang). Kept buying through 2026 (~1.1M sh / ~$21M in Q1, plus a ~670K-share open-market tranche and discrete $41M/$8.8M/$606k buys). Standalone PT ~$50; standstill expired June 18 2026.
Leadership is INTERIM: Co-CEOs Warren Foust (Pres/COO) + Deborah Andrews (CFO) since Feb 1 2026; permanent-CEO search still open. A named permanent CEO would signal standalone-execution vs re-opened sale.
China = ~51% of Q1 2026 net sales ($47.4M of $93.5M). Historically China carries a higher share of trade receivables than of revenue watch collectability / sell-in durability on the Q2 print.
Q2 2026 earnings ~early-to-mid Aug (Q2 2025 reported Aug 6 2025; revenue consensus ~$84M). First test of whether the China EVO+ recovery is durable vs a destocking-rebound bounce. Confirm exact date on investors.staar.com before any blackout-window sizing.
PT dispersion: consensus ~$27.81–29.67 (≈ spot) vs Wedbush $40 (upgraded May 29 2026 from $26) vs Broadwood $50 upside above ~$30 is M&A/activist-contingent, not organic. 52-wk range $15.59–$35.87; 2025 China destocking took it to the $15.59 low.
Supply/tariff: management guiding to 100% Swiss manufacturing for China EVO/EVO+ in 2026 (removes US-tariff exposure); 2026 spend ~$225M, gross margin ~75%.
THEME: STAA is ophthalmic medtech (EVO/EVO+ ICL myopia implants), heavily China-levered NOT a biotech/therapeutics name. Prior dossiers mis-tagged it as biotech-precision-therapeutics / rare-disease-approvals; do not revert. Also dropped bogus semi-foundry-equipment / managed-care-health-services tags.
EARNINGS DATE CONFLICT: company press release (2026-07-16) states Q2 results on 2026-08-12. Some vendors (stockanalysis.com) carry 2026-08-05. Confirm on investors.staar.com before any blackout-window sizing.
Q2 2026 prelim (2026-07-16): net sales >$90M vs $44.3M Q2 2025 (+103%). In line with $90.2M consensus, above Canaccord $88.4M. But SEQUENTIALLY BELOW Q1's $93.52M. Market reaction: -8.76% to $26.44 on 2026-07-17, gap from $28.98 close to $26.75 open.
Comp cliff: Q2 2025 $44.3M was the destocking trough. From Q3 2026 the base normalizes triple-digit YoY growth headlines stop after this quarter.
Regional split Q2: China up sequentially, APAC solid, Americas double-digit growth, EMEA total DOWN low-single-digit on Middle East conflict (EMEA ex-Middle East grew double digits). Management warned intensifying geopolitical pressure could hit future revenue growth.
Deal history: Alcon $28 (Aug 2025) -> $30.75 amended ($1.6B) -> REJECTED at 2026-01-06 special meeting -> terminated. ISS called the process 'deeply flawed'. Don't anchor entries to the dead takeout price.
M&A binary is SPENT: Broadwood standstill (no special-meeting demand) expired 2026-06-18, same day as the annual meeting. Meeting produced director re-elections, +3.9M share equity plan, BDO ratification, say-on-pay pass and NO sale process or strategic review. One month on, still nothing.
Ownership: Broadwood ~31% (Bradsher + LeBuhn on board), Yunqi Capital 6.5% (Wang on board), via 2026-01-15 cooperation agreement. Institutions 96.7%. Effective float is small moves exaggerate in both directions.
Leadership INTERIM since 2026-02-01: co-CEOs Warren Foust (Pres/COO) + Deborah Andrews (CFO), $375k RSU each. Permanent-CEO search open ~6 months. Chair Yeu and ex-CEO Farrell left the board Jan 2026. A credible external hire is the biggest single re-rate catalyst.
Technical state as of 2026-07-17: price $26.44, 50-DMA $29.43 (BROKEN, now resistance), 200-DMA $23.80 (rising), 52wk range $15.59-$35.87, beta 1.23, mkt cap ~$1.3B, 49.79M shares.
Fundamentals: TTM revenue $290.38M (+4.0%), TTM net income -$21.03M, EPS -$0.42, forward P/E 34.26. Quick ratio 4.31, current ratio 5.12, D/E 0.09.
Analyst dispersion: consensus $27.81 (3 Buy / 6 Hold / 2 Sell panel) or $29.67 (11-analyst Buy tally) both at/near spot. Wedbush $40 reiterated 2026-07-16 (Michael Piccolo, upgraded 2026-05-29 from Neutral, PT $26->$40), Canaccord $32, Wells Fargo $25. Broadwood's own case ~$50. Upside above ~$32 is activist/M&A-contingent, not organic.
China concentration: Q1 2026 China distributors = 51% of net sales ($47.4M of $93.52M) but 57% of trade receivables. Watch collectability and sell-in pull-forward the 2025 destocking took the stock to $15.59.
Constructive re-entry conditions: higher low above the 200-day PLUS a reclaim of the $29.43 50-day on expanding volume. Do not buy the gap on the strength of the Wedbush $40 target that target predates the sequential deceleration.
Next 13F deadline 2026-08-14 reveals Broadwood/Yunqi June-quarter positioning cleanest read on whether the anchor holder is still accumulating.

Related · shared themes

MRCY

Mercury Systems Inc

Defense-electronics turnaround re-rating inside an accelerating modernization tape: Q3 FY26 (2026-05-06) printed record bookings $348M (+73.7% YoY), 1.48 book-to-bill, record ~$1.6B backlog and +46% EBITDA, with FCF guided positive. But the stock just reversed ~16% off its $128.45 ATH; the ~2026-08-10 Q4/full-year print is the next binary.

MEDIUM

SIMO

Silicon Motion Technology Corporation

NAND-controller toll-booth on the steepest flash shortage in ~15 years: TrendForce H1 2026 contract +>100% cumulative, H2 still rising with no capacity adds. Q1 record +105% YoY, sell-side chasing to $400/$450. Fundamental leg ACCELERATING, but the tape is digesting a 4x into insider selling the 2026-07-29 Q2 print is the next binary.

MEDIUM

XPO

XPO, Inc.

Freight-cycle upturn is the accelerating narrative: LTL volume and contract pricing re-accelerating after a multi-year trucking recession, with SAIA May tonnage +8.4% confirming the cluster. XPO layers operating-ratio self-help (Q1 LTL OR 83.9%, -200bps YoY) on top. The 2026-07-30 Q2 print is the binary that validates or breaks the "comfortably ahead" yield guide.

MEDIUM

HNGE

Hinge Health, Inc.

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.

LOW